SCHEMBL721218

SCHEMBL721218

Cc1c(C(Cl)C2CCCCC2)oc2ccc(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.43
KCNH2 Q12809 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
AHR P35869 3/20 0.36
MAPT P10636 2/20 0.36
HRH4 Q9H3N8 2/20 0.35
PTGS2 P35354 1/20 0.35
PKM P14618 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ALDH1A1 P00352 1/20 0.35
AKR1B1 P15121 1/20 0.34
CDC7 O00311 1/20 0.34
CIT O14578 1/20 0.34
CYP1A2 P05177 1/20 0.34
PIM1 P11309 1/20 0.34
CSNK2A2 P19784 1/20 0.34
GSK3B P49841 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721579 0.88 NPC1 (0.41) KCNH2NPC1RAB9AMAPTHRH4
SCHEMBL718379 0.85 NPC1 (0.52) NPC1RAB9AMAPTRXFP1ALDH1A1
SCHEMBL721192 0.85 MCL1 (0.45) MCL1KCNH2NPC1RAB9AAHR
SCHEMBL718939 0.83 RAB9A (0.54) NPC1RAB9AMAPTALDH1A1DYRK1A
SCHEMBL721329 0.82 HRH4 (0.36) NPC1RAB9AHRH4ALDH1A1
SCHEMBL716824 0.82 NPC1 (0.48) NPC1RAB9AMAPTALDH1A1
SCHEMBL719533 0.77 NPC1 (0.41) KCNH2NPC1RAB9AALDH1A1
SCHEMBL718571 0.77 L3MBTL1 (0.50) NPC1RAB9APKMALDH1A1
SCHEMBL12248491 0.75 MCL1 (0.53) MCL1KCNH2AHRPKMRXFP1
SCHEMBL717053 0.72 NPC1 (0.45) KCNH2NPC1RAB9AALDH1A1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MCL1 900/4885KCNH2 2392/4885NPC1 902/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MCL1 900/4885KCNH2 2392/4885NPC1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.